domains/health/glp-1-access-structure-inverts-need-creating-equity-paradox.md

@@ -46,3 +46,10 @@ The Medicare GLP-1 Bridge program provides concrete evidence that the access inv
 **Source:** KFF 2025 national poll, N=1,309 adults
 
 KFF national poll finds only 23% of obese/overweight adults currently taking GLP-1s, meaning 77% of the eligible population is not accessing treatment despite drug availability. Among current users, 56% report difficulty affording medications, and 27% of insured users paid full cost out-of-pocket. Cost-driven discontinuation (14%) rivals side effect discontinuation (13%), demonstrating affordability as a primary access barrier.
+
+
+## Supporting Evidence
+
+**Source:** KFF Poll 2025
+
+KFF national poll finds only 23% of obese/overweight adults currently taking GLP-1s, meaning 77% of the eligible population is not accessing treatment despite drug availability. Among current users, 56% report difficulty affording medications, and 27% of insured users paid full cost out-of-pocket. The age 65+ population shows only 9% usage rate, directly reflecting Medicare's statutory exclusion of weight-loss drugs. 14% of former users stopped due to cost (comparable to the 13% who stopped due to side effects).

domains/health/glp1-access-inverted-by-cardiovascular-risk-creating-efficacy-translation-barrier.md

@@ -25,3 +25,10 @@ The Lancet February 2026 editorial provides highest-prestige institutional frami
 # GLP-1 anti-obesity drug access is structurally inverted: populations with greatest cardiovascular mortality risk face the highest costs and lowest coverage rates, preventing clinical efficacy from reaching population-level impact
 
 ICER's 2025 access analysis reveals a structural inversion: the populations with greatest cardiovascular mortality risk (lower SES, Black Americans, Southern rural residents) face the highest out-of-pocket costs and lowest insurance coverage rates for GLP-1 anti-obesity medications. In Mississippi, continuous GLP-1 treatment costs approximately 12.5% of annual income for the typical individual. Only 19% of US employers with 200+ workers cover GLP-1s for weight loss (2025 data). Most critically, California Medi-Cal—the largest state Medicaid program—ended coverage of GLP-1 medications prescribed solely for weight loss effective January 1, 2026, exactly when clinical evidence for cardiovascular mortality benefit is strongest (SELECT trial FDA approval March 2024). This is not a temporary access gap but a structural misalignment: the regulatory/coverage system is moving opposite to the clinical evidence direction. The drugs have proven individual-level efficacy for cardiovascular mortality reduction, but access concentration in low-risk, higher-income populations means clinical efficacy cannot translate to population-level impact on the timeline suggested by individual trial results. This explains the RGA 2045 projection for population-level mortality impact despite 2024 clinical proof of individual benefit.
+
+
+## Supporting Evidence
+
+**Source:** KFF Poll 2025
+
+Among diagnosed populations with highest cardiovascular benefit potential, uptake remains limited: 45% of diabetes patients and 29% of heart disease patients currently using GLP-1s. The 77% non-uptake among eligible obese/overweight adults quantifies the population-level access gap that prevents efficacy translation from clinical trials to real-world mortality impact.

domains/health/glp1-long-term-persistence-ceiling-14-percent-year-two.md

@@ -23,3 +23,10 @@ Despite the near-doubling of year-one persistence rates, Prime Therapeutics data
 **Source:** KFF 2025 poll
 
 Cost is a major driver of discontinuation: 14% of former GLP-1 users stopped due to cost, matching the 13% who stopped due to side effects. Among current users, 56% report difficulty affording medications, suggesting cost pressure operates throughout the treatment duration, not just at initiation. The 27% of insured users paying full out-of-pocket cost indicates insurance coverage gaps contribute to persistence failures.
+
+
+## Extending Evidence
+
+**Source:** KFF Poll 2025
+
+Cost-driven discontinuation represents a distinct adherence failure mode: 14% of former GLP-1 users stopped due to affordability (vs. 13% due to side effects). This cost-driven discontinuation operates independently of the clinical side effect pathway and affects even insured populations (55% of insured users report affordability challenges).

domains/health/medicare-glp1-bridge-lis-exclusion-structurally-denies-lowest-income-access.md

@@ -17,3 +17,10 @@ related: ["medicaid-glp1-coverage-reversing-through-state-budget-pressure", "glp
 # The Medicare GLP-1 Bridge program's Low-Income Subsidy exclusion structurally denies the lowest-income Medicare beneficiaries access to GLP-1 obesity coverage despite nominal eligibility
 
 The Medicare GLP-1 Bridge program (July-December 2026) covers Wegovy and Zepbound at a fixed $50 copayment for eligible Part D beneficiaries. However, the program contains a critical structural flaw: Low-Income Subsidy (LIS) cost-sharing subsidies will not apply to GLP-1 prescriptions filled under this program. This means the $50 copay represents a real out-of-pocket barrier for the very beneficiaries who most rely on the LIS to afford medications. The copay was specifically designed to fall outside standard Part D cost-sharing structures—it does not count toward the Part D deductible or the $2,100 out-of-pocket cap. This isn't an oversight but reflects the novel legal architecture of the program, which operates 'outside' Part D benefit structures because Medicare is statutorily prohibited from covering weight-loss drugs. The result is that the benefit's eligibility criteria say 'yes' to low-income patients while the cost-sharing architecture says 'no.' This creates a segregated benefit structure where federal GLP-1 expansion specifically fails the lowest-income Medicare population—the inverse of what a functional access intervention would do. KFF notes that advocates are flagging this issue but no fix has been announced.
+
+
+## Supporting Evidence
+
+**Source:** KFF Poll 2025
+
+The age 65+ population shows only 9% GLP-1 usage rate compared to 22% for ages 50-64, providing direct empirical confirmation of Medicare's structural exclusion effect. This represents the lowest usage rate across all age groups despite Medicare beneficiaries having the highest obesity burden and worst health outcomes.